

Hans-Peter Brunner-La Rocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4481812/publications.pdf>

Version: 2024-02-01

120
papers

4,307
citations

136740

32
h-index

123241

61
g-index

121
all docs

121
docs citations

121
times ranked

5824
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of signs and symptoms in heart failure patients using remote telemonitoring. <i>Journal of Telemedicine and Telecare</i> , 2024, 30, 180-185.	1.4	2
2	Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 761-769.	1.8	11
3	Acute heart failure and iron deficiency: a prospective, multicentre, observational study. <i>ESC Heart Failure</i> , 2022, 9, 398-407.	1.4	11
4	Diabetes and treatment of chronic heart failure in a large real-world heart failure population. <i>ESC Heart Failure</i> , 2022, 9, 353-362.	1.4	13
5	What to consider when implementing a tool for timely recognition of palliative care needs in heart failure: a context-based qualitative study. <i>BMC Palliative Care</i> , 2022, 21, 1.	0.8	11
6	Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. <i>ESC Heart Failure</i> , 2022, 9, 1463-1470.	1.4	9
7	Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study. <i>ESC Heart Failure</i> , 2022, 9, 363-372.	1.4	17
8	Circulating levels and prognostic cutoffs of sST2, hsTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	1.4	15
9	Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF. <i>Clinical Research in Cardiology</i> , 2021, 110, 1221-1233.	1.5	5
10	Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 957-965.	0.8	13
11	Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting? Letter regarding the article "Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-ORP Heart Failure Long-Term Registry". <i>European Journal of Heart Failure</i> , 2021, 23, 342-342.	2.9	2
12	Soluble CD146: an underreported novel biomarker of congestion: a comment on a review concerning congestion assessment and evaluation in acute heart failure. <i>Heart Failure Reviews</i> , 2021, 26, 731-732.	1.7	3
13	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 176-185.	2.3	18
14	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	1.0	96
15	Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial. <i>European Journal of Heart Failure</i> , 2021, 23, 302-309.	2.9	24
16	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	1.5	20
17	Spirolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, . .	1.4	4
18	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 973-982.	2.9	65

#	ARTICLE	IF	CITATIONS
19	Determinants of acceptance of patients with heart failure and their informal caregivers regarding an interactive decision-making system: a qualitative study. <i>BMJ Open</i> , 2021, 11, e046160.	0.8	11
20	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy—A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 933-944.	2.9	34
21	A global longitudinal strain cut-off value to predict adverse outcomes in individuals with a normal ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 4343-4345.	1.4	17
22	A Home Hospitalisation Strategy for Patients with an Acute Episode of Heart Failure Using a Digital Health-Supported Platform: A Multicentre Feasibility Study – A Rationale and Study Design. <i>Cardiology</i> , 2021, 146, 793-800.	0.6	6
23	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
24	Future perspective of heart failure care: benefits and bottlenecks of artificial intelligence and eHealth. <i>Future Cardiology</i> , 2021, 17, 917-921.	0.5	5
25	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1577-1596.	2.9	23
26	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	1.9	20
27	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 23, 74-84.	0.5	17
28	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 28-36.	0.6	1
29	Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	1
30	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. <i>Clinical Research in Cardiology</i> , 2020, 109, 22-33.	1.5	19
31	Value of Speckle Tracking-Based Deformation Analysis in Screening Relatives of Patients With Asymptomatic Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 549-558.	2.3	40
32	Validation of the HFA-EFF score for the diagnosis of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 413-421.	2.9	101
33	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	2.9	26
34	Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. <i>International Journal of Cardiology</i> , 2020, 300, 245-251.	0.8	19
35	Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008727.	2.1	6
36	Serum Matrix Metalloproteinases and Left Atrial Remodeling—The Hoorn Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4944.	1.8	8

#	ARTICLE	IF	CITATIONS
37	The importance of electrocardiographic follow-up in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2380-2382.	2.9	0
38	The Reply. <i>American Journal of Medicine</i> , 2020, 133, e330-e332.	0.6	1
39	Putting AI at the centre of heart failure care. <i>ESC Heart Failure</i> , 2020, 7, 3257-3258.	1.4	14
40	Sex differences in circulating proteins in heart failure with preserved ejection fraction. <i>Biology of Sex Differences</i> , 2020, 11, 47.	1.8	12
41	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. <i>Alzheimer's and Dementia</i> , 2020, 16, e042892.	0.4	0
42	Professionals guidance about palliative medicine in chronic heart failure: a mixed-method study. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002580.	0.8	4
43	Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study. <i>Cardiovascular Diabetology</i> , 2020, 19, 88.	2.7	18
44	Characteristics for a tool for timely identification of palliative needs in heart failure: The views of Dutch patients, their families and healthcare professionals. <i>European Journal of Cardiovascular Nursing</i> , 2020, 19, 711-720.	0.4	10
45	Atrial fibrillation in chronic heart failure patients with reduced ejection fraction: The CHECK-HF registry. <i>International Journal of Cardiology</i> , 2020, 308, 60-66.	0.8	9
46	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. <i>European Journal of Heart Failure</i> , 2020, 22, 1586-1597.	2.9	16
47	Reasons for readmission after hospital discharge in patients with chronic diseases—Information from an international dataset. <i>PLoS ONE</i> , 2020, 15, e0233457.	1.1	39
48	Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF. <i>Clinical Research in Cardiology</i> , 2020, 109, 1155-1164.	1.5	12
49	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). <i>Biomarkers</i> , 2020, 25, 201-211.	0.9	26
50	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1711-1723.	2.9	43
51	What do we need to better understand the role of biomarkers in heart failure?. <i>International Journal of Cardiology</i> , 2020, 304, 93-94.	0.8	1
52	Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 701-709.	2.9	18
53	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	2.9	50
54	Cerebral cortical microinfarcts: A novel MRI marker of vascular brain injury in patients with heart failure. <i>International Journal of Cardiology</i> , 2020, 310, 96-102.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0233457.		0
56	Title is missing!. , 2020, 15, e0233457.		0
57	Title is missing!. , 2020, 15, e0233457.		0
58	Title is missing!. , 2020, 15, e0233457.		0
59	Unravelling heart failure nursesâ€™ education: Content comparison of heart failure nursesâ€™ education in three European Society of Cardiology states and the Heart Failure Association heart failure curriculum. <i>European Journal of Cardiovascular Nursing</i> , 2019, 18, 711-719.	0.4	3
60	Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2466-2477.	1.2	58
61	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. <i>Stroke</i> , 2019, 50, 3369-3375.	1.0	29
62	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	0.8	28
63	Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. <i>American Journal of Medicine</i> , 2019, 132, e679-e692.	0.6	15
64	Nonfocal transient neurological attacks are related to cognitive impairment in patients with heart failure. <i>Journal of Neurology</i> , 2019, 266, 2035-2042.	1.8	1
65	Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1399-1407.	0.8	31
66	Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. <i>EPMA Journal</i> , 2019, 10, 445-464.	3.3	96
67	Loop diuretics in chronic heart failure: how to manage congestion?. <i>Heart Failure Reviews</i> , 2019, 24, 17-30.	1.7	15
68	The use of diuretics in heart failure with congestion â€” a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 137-155.	2.9	605
69	Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 13-21.	1.9	122
70	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
71	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004228.	1.6	65
72	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. <i>European Heart Journal</i> , 2018, 39, 864-873.	1.0	132

#	ARTICLE	IF	CITATIONS
73	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
74	An old debate still in the "phase?". <i>European Journal of Heart Failure</i> , 2018, 20, 557-559.	2.9	0
75	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> . 2018, 20, 1081-1099.	2.9	57
76	The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study. <i>Cerebrovascular Diseases Extra</i> , 2018, 7, 140-152.	0.5	44
77	Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 55.	0.6	10
78	Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e005220.	1.6	51
79	Guiding Heart Failure Therapy After GUIDE-IT. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2563-2566.	1.2	1
80	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	1.2	126
81	Risk stratification and role for additional diagnostic testing in patients with acute chest pain and normal high-sensitivity cardiac troponin levels. <i>PLoS ONE</i> , 2018, 13, e0203506.	1.1	1
82	Helping to understand heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 2836-2838.	1.0	2
83	Novel concept to guide systolic heart failure medication by repeated biomarker testing—results from TIME-CHF in context of predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2018, 9, 161-173.	3.3	10
84	Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. <i>European Journal of Internal Medicine</i> , 2018, 57, 61-69.	1.0	11
85	Worsening Renal Function in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 70-72.	1.2	1
86	N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF. <i>Journal of Cardiac Failure</i> , 2017, 23, 382-389.	0.7	13
87	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
88	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017, 19, 821-836.	2.9	252
89	Just air good enough in pulmonary hypertension?. <i>European Heart Journal</i> , 2017, 38, 1169-1171.	1.0	1
90	Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (<sc>TIME-CHF</sc>). <i>European Journal of Heart Failure</i> , 2017, 19, 1586-1596.	2.9	108

#	ARTICLE	IF	CITATIONS
91	Pulmonary and right ventricular dysfunction are frequently present in heart failure irrespective of left ventricular ejection fraction. <i>Heart Asia</i> , 2017, 9, e010914.	1.1	4
92	Prognostic Value of the Change in Heart Rate From the Supine to the Upright Position in Patients With Chronic Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	3
93	Relevance of cardiac parvovirus <scp>B19</scp> in myocarditis and dilated cardiomyopathy: review of the literature. <i>European Journal of Heart Failure</i> , 2016, 18, 1430-1441.	2.9	108
94	Acute chest pain in the high-sensitivity cardiac troponin era: A changing role for noninvasive imaging?. <i>American Heart Journal</i> , 2016, 177, 102-111.	1.2	20
95	Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 278-285.	0.9	12
96	Treatment of heart failure in nursing home residents. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 44-50.	0.2	6
97	Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. <i>European Journal of Heart Failure</i> , 2015, 17, 1252-1261.	2.9	95
98	Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane based multiplexed immunoassay. <i>Journal of Translational Medicine</i> , 2015, 13, 129.	1.8	40
99	Heart failure in nursing home residents; a cross-sectional study to determine the prevalence and clinical characteristics. <i>BMC Geriatrics</i> , 2015, 15, 167.	1.1	23
100	Challenges in personalised management of chronic diseases—heart failure as prominent example to advance the care process. <i>EPMA Journal</i> , 2015, 7, 2.	3.3	35
101	Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 1006-1014.	2.9	198
102	Biomarker Guided Therapy in Chronic Heart Failure. <i>Cardiac Failure Review</i> , 2015, 1, 96.	1.2	5
103	Impact of worsening renal function related to medication in heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 159-168.	2.9	37
104	Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. <i>International Journal of Cardiology</i> , 2015, 191, 286-293.	0.8	9
105	Inflammation in HFpEF: Key or circumstantial?. <i>International Journal of Cardiology</i> , 2015, 189, 259-263.	0.8	51
106	Differential Prognostic Impact of Resting Heart Rate in Older Compared With Younger Patients With Chronic Heart Failure—Insights From TIME-CHF. <i>Journal of Cardiac Failure</i> , 2015, 21, 347-354.	0.7	7
107	Clinical Interpretation of Elevated Concentrations of Cardiac Troponin T, but Not Troponin I, in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 884-891.	1.2	16
108	Prognostic Relevance of Gene-Environment Interactions in Patients With Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1313-1323.	1.2	76

#	ARTICLE	IF	CITATIONS
109	Iron i.v. in heart failure: ready for implementation?. <i>European Heart Journal</i> , 2015, 36, 645-647.	1.0	10
110	Long-Term Effect of a School-Based Physical Activity Program (KISS) on Fitness and Adiposity in Children: A Cluster-Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e87929.	1.1	79
111	Risk Stratification With the Use of Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements During Admission and Early After Discharge in Heart Failure Patients: Post Hoc Analysis of the PRIMA Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 881-890.	0.7	14
112	Heart failure and COPD: Time to SHIFT?. <i>International Journal of Cardiology</i> , 2014, 172, 293-294.	0.8	5
113	Interaction Between Pulmonary Hypertension and Diastolic Dysfunction in an Elderly Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2014, 20, 98-104.	0.7	10
114	Evaluation of Left Ventricular Endocardial Cardiac Resynchronization Therapy in a Non-responder with Ventricular Arrhythmias. <i>Indian Pacing and Electrophysiology Journal</i> , 2014, 14, 32-36.	0.3	0
115	Clinical Long-Term Response to Cardiac Resynchronization Therapy Is Independent of Persisting Echocardiographic Markers of Dyssynchrony. <i>Cardiology Research</i> , 2014, 5, 163-170.	0.5	1
116	Heart omics™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	0.7	24
117	Cost-Effectiveness of N-Terminal Pro-B-Type Natriuretic-Guided Therapy in Elderly Heart Failure Patients. <i>JACC: Heart Failure</i> , 2013, 1, 64-71.	1.9	44
118	End-of-life preferences of elderly patients with chronic heart failure. <i>European Heart Journal</i> , 2012, 33, 752-759.	1.0	95
119	Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). <i>European Heart Journal</i> , 2007, 28, 719-725.	1.0	74
120	Better outcome at lower costs after implementing a CRT care pathway: comprehensive evaluation of real-world data. <i>ESC Heart Failure</i> , 0, , .	1.4	1